Roche presents positive phase Ib data at AACR 2023, reinforcing the potential of its KRAS G12C inhibitor divarasib in advanced solid tumours

In the phaseIb GO42144 study,divarasib in combination withcetuximab, an anti-EGFR therapy, led to a confirmed overall response in 62% of people with advanced colorectal cancerThe treatment combination demonstrated a manageable safety profileThe data presented at AACR 2023further support Roche ' s programme to developdivarasib as single-agent or in combination for treating solid tumoursBasel, 18 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from the phase Ib GO42144 study, which show that treatment with the KRAS G12C inhibitor, divarasib (GDC-6036), in combination with anti-EGFR therapy, cetuximab, led to a confirmed overall response in 62% of people with advanced or metastatic KRAS G12C-positive colorectal cancer (CRC). Divarasib in combination with cetuximab demonstrated a manageable safety profile. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting, 17 April 2023 at 14:50 ET.1CRC is the third most common cancer worldwide and the global burden is growing, with the incidence rate predicted to increase by 56% between 2020 and 2040 to more than three million new cases per year.2It is also one of the leading causes of cancer-related deaths, withKRAS mutations in CRC associated with poorer prognosis and increased tumour aggressiveness.3“These data reinforce the potentially best-in-class-profile of divarasib together with EGFR inhibition in people who have KRAS G12C mutated CRC and support further inv...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news